The financing round was led by The FSE Group with backing from new and existing angel investors.
"This funding marks an important step in commercialising our Flip product platform and validating new assays with strategic partners across sectors where rapid, decentralised testing can make a meaningful difference,. Built on years of scientific and engineering development, Flip is designed to give researchers faster, simpler tools for detecting pathogens and contaminants, helping to prevent disease and protect products, biological processes and the environment."
The biotechnology firm secured backing from the South West Investment Fund to expand manufacturing capabilities.
"We’re delighted to provide this investment from the South West Investment Fund to support genuinely breakthrough materials science in the delivery of meaningful carbon reductions. With strong commercial interest already in place and a clear plan to scale production, Mykor is well-positioned to play a significant role in decarbonising the built environment while building a high-growth, internationally relevant business."
The Series C round was co-led by Oxford Science Enterprises and Supernova Invest to support product development.
"When we helped spin Moa out from the University of Oxford’s Plant Sciences Department in 2017, we saw that its technology platform had a unique and important approach to address the market’s need for herbicides capable of breaking weed resistance,"
The round was led by Waseda University Ventures to support clinical studies and regulatory approval for the device.
"We have a strong base of evidence that neuroplasticity can be induced by detecting a motor command and applying artificial sensory feedback – guiding the brain to remake connections. Neubond has made rapid progress in translating this laboratory science into a simple device that patients can use at home"
SCVC led the pre-seed round with backing from Deep Science Ventures and Cambridge Enterprise VC to help the startup expand its team and partnerships.
"Cellular machinery still rejects these therapies, limiting long-term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design,"
.png)
-20webclip.png)
